This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ONCE Spark Therapeutics (ONCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Spark Therapeutics Stock (NASDAQ:ONCE) 30 days 90 days 365 days Advanced Chart Get Spark Therapeutics alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$110.05▼$113.5752-Week Range$34.53▼$114.20VolumeN/AAverage Volume891,560 shsMarket Capitalization$6.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Read More… Receive ONCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCE Stock News HeadlinesHow Spark's layoffs could affect University City real estateApril 11, 2025 | bizjournals.comDespite Spark's massive layoffs, co-founder Jeff Marrazzo says its legacy will endureApril 9, 2025 | bizjournals.comWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.June 30 at 2:00 AM | Crypto Swap Profits (Ad)Spark Therapeutics is laying off 337 people, more than half its workforce, starting in MayApril 3, 2025 | msn.comSpark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downsMarch 4, 2025 | msn.comPfizer shelves Beqvez, a Spark Therapeutics developed productFebruary 24, 2025 | bizjournals.comSpark Therapeutics co-founder back at the helm of a Philadelphia gene therapy companyJanuary 14, 2025 | bizjournals.comBitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business liveNovember 11, 2024 | msn.comSee More Headlines ONCE Stock Analysis - Frequently Asked Questions How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) posted its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to analysts' expectations of $29.44 million. Spark Therapeutics had a negative trailing twelve-month return on equity of 59.10% and a negative net margin of 358.41%. When did Spark Therapeutics IPO? Spark Therapeutics (ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spark Therapeutics investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Meta Platforms (META), Alibaba Group (BABA), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/07/2018Today6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONCE CIK1609351 Webwww.sparktx.com Phone888-772-7560FaxN/AEmployees368Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.82 million Net Margins-358.41% Pretax MarginN/A Return on Equity-59.10% Return on Assets-33.13% Debt Debt-to-Equity Ratio0.35 Current Ratio4.67 Quick Ratio4.35 Sales & Book Value Annual Sales$64.72 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$13.15 per share Price / Book0.01Miscellaneous Outstanding Shares38,523,000Free FloatN/AMarket Cap$6.94 million OptionableNo Data Beta2.05 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ONCE) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredConsumer apocalypse imminent (7 ominous red flags)The #1 Gold play right now (not a miner, ETF, or bullion) Gold is up 237% since 2008... but one gold invest...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spark Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Spark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.